Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals

Jeffrey R. Strich; Ahmed Ullah Mishuk; Guoqing Diao; Alexander Lawandi; Willy Li; Cumhur Y. Demirkale; Ahmed Babiker; Alex Mancera; Bruce Swihart; Morgan Walker; Christina Yek; Maniraj Neupane; Nathaniel De Jonge; Sarah Warner; Sameer S. Kadri; Jeffrey R. Strich; Ahmed Ullah Mishuk; Guoqing Diao; Alexander Lawandi; Willy Li; Cumhur Y. Demirkale; Ahmed Babiker; Alex Mancera; Bruce Swihart; Morgan Walker; Christina Yek; Maniraj Neupane; Nathaniel De Jonge; Sarah Warner; Sameer S. Kadri

doi:10.7326/m23-2309

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The U.S. antibiotic market failure has threatened future innovation and supply. Understanding when and why clinicians underutilize recently approved gram-negative antibiotics might help prioritize the patient in future antibiotic development and potential market entry rewards.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Strich et al. (2024) studied this question.

synapsesocial.com/papers/68e6e657b6db6435876613da https://doi.org/10.7326/m23-2309

View at Publisher

Ask AI

Bookmark

Share

Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals

Ask about this paper

Abstract

Discussion

Cite This Study

Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading